Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | PER2 | O15055 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15368463 | 0.89 | ACE (0.61) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL12893384 | 0.89 | ACE (0.61) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL5312378 | 0.85 | PIK3CD (0.55) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL3715423 | 0.83 | PIK3CD (0.53) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL24879759 | 0.80 | PIK3CD (0.50) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL6628684 | 0.80 | PIK3CD (0.50) | ACEPIK3CDCHRM2CHRM4CHRM5 | |
| SCHEMBL31443583 | 0.79 | — | — | |
| SCHEMBL9789687 | 0.78 | ACE (0.61) | ACEPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9789659 | 0.78 | ACE (0.61) | ACEPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9789660 | 0.78 | ACE (0.61) | ACEPOLBCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1094895-B1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN NV (BE) | 2004-02-04 | — | — | EP | claimed |
| EP-1094895-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| US-6013596-A | A POLYETHER POLYMERIZATION CATALYST CONSISTS OF A DOUBLE METAL CYANIDE COMPOUND, AN ORGANIC COMPLEXING AGENT COMPRISING C3-C5 ALIPHATIC ALCOHOL AND CYCLIC, BIDENTATE LACTAM OR LACTONE COMPOUND | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 2000-01-11 | — | — | US | claimed |
| WO-1999059719-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 1999-11-25 | — | — | WO | claimed |
| WO-2022204065-A1 | IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-1094895-B1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN NV (BE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1094895-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 2001-05-02 | — | — | EP | disclosed |
| US-6013596-A | A POLYETHER POLYMERIZATION CATALYST CONSISTS OF A DOUBLE METAL CYANIDE COMPOUND, AN ORGANIC COMPLEXING AGENT COMPRISING C3-C5 ALIPHATIC ALCOHOL AND CYCLIC, BIDENTATE LACTAM OR LACTONE COMPOUND | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1999059719-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 1999-11-25 | — | — | WO | disclosed |